Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 13/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 13/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.50 |
| ▸ | HTT | P42858 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | MITF | O75030 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | NSD2 | O96028 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16296711 | 0.88 | NSD2 (0.58) | APAF1RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL16297001 | 0.87 | APAF1 (0.58) | APAF1RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL16297004 | 0.87 | MAPT (0.67) | APAF1RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL16296931 | 0.86 | MAPT (0.55) | APAF1RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL16297036 | 0.85 | APAF1 (0.57) | APAF1RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL16296645 | 0.82 | APAF1 (0.58) | APAF1RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL16296988 | 0.82 | APAF1 (0.58) | APAF1RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL16297072 | 0.81 | APAF1 (0.55) | APAF1RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL16296987 | 0.80 | MAPT (0.56) | APAF1RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL19625608 | 0.79 | APAF1 (0.67) | APAF1RAB9ANPC1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220128562-A1 | BIOMARKERS PREDICTIVE OF CANCER CELL RESPONSE TO ML329 OR A DERIVATIVE THEREOF | UNIVERSITY OF KANSAS | 2022-04-28 | — | — | US | disclosed |
| US-20170334842-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | UNIVERSITY OF KANSAS | 2017-11-23 | — | — | US | disclosed |
| US-20170334842-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | UNIVERSITY OF KANSAS | 2017-11-23 | — | — | US | disclosed |
| US-20170334842-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | UNIVERSITY OF KANSAS | 2017-11-23 | — | — | US | disclosed |
| US-9745261-B2 | Inhibitors of the MITF molecular pathway | THE GENERAL HOSPITAL CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745261-B2 | Inhibitors of the MITF molecular pathway | THE GENERAL HOSPITAL CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745261-B2 | Inhibitors of the MITF molecular pathway | THE GENERAL HOSPITAL CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160130222-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | THE BROAD INSTITUTE, INC. | 2016-05-12 | — | — | US | disclosed |
| US-20160130222-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | THE BROAD INSTITUTE, INC. | 2016-05-12 | — | — | US | disclosed |
| US-20160130222-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | THE BROAD INSTITUTE, INC. | 2016-05-12 | — | — | US | disclosed |
| EP-3007688-A2 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | The General Hospital Corporation (US) | 2016-04-20 | — | — | EP | disclosed |
| WO-2014201016-A2 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014201016-A2 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130222-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | MITF, TFEB, TYR | APAF1 2437/4885RAB9A 805/4885NPC1 2581/4885 |
| US-20170334842-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | MITF, TFEB, TYR | APAF1 2521/4885RAB9A 746/4885NPC1 2867/4885 |
| US-20220128562-A1 | BIOMARKERS PREDICTIVE OF CANCER CELL RESPONSE TO ML329 OR A DERIVATIVE THEREOF | NQO1, KEAP1, NFE2L2 | APAF1 1675/4885RAB9A 1566/4885NPC1 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.